Documenti di Didattica
Documenti di Professioni
Documenti di Cultura
1-Bilirubin production.
2-Transport in blood.
3-Hepatocellular uptake.
4-Intracellular transport in hepatocytes.
5-Conjugation with glucuronic acid.
6-Secretion into bile ducts.
7- Intestinal metabolism.
8- Renal excretion of bilirubin
9- Renal excretion oh urobilinogen
1-BILIRUBIN PRODUCTION
Bilirubin is the terminal product of heme metabolism. Heme is present in hemoglobin and in other
oxidative compounds such as hepatic mitochondrial and microsomal cytochromes (P-450). Thus plasma
bilirubin is part erythropoietic and part non-erythropoietic. Approximately, 85 % erythropoietic and 15%
non-erythropoietic.
The erythropoietic fraction originates from two sources: the circulating normal aging red cells and the
immature defective red cells of the bone marrow. The daily production of bilirubin is 250 to 350 mg.
Shunt bilirubin is called that portion that does not originate from senescent circulating red cells but
originates from immature and defective red cells (7%) and from non- hemoglobin heme compounds,
particularly from hepatic cytochromes and from myoglobin. These two fractions were discovered by
labeling hemoglobin with a radioactive glycin, and observing that one fraction (78 %) of bilirubin is
excreted in the feces in 120 days and another fraction is excreted in 10 days or less. The first was called
late labeled bilirubin, the second was called early labeled bilirubin or shunt bilirubin. Shunt bilirubin
may be markedly elevated in certain pathologic states: sideroblastic anemia, megaloblastic anemia,
erythroleukemia, lead poisoning and a congenital disorder called "idiopathic dyserythropoietic
jaundice". The patients affected by this condition do not have hemolysis. They have hyperbilirubinemia
and jaundice. The hyprbilirubinemia is due to shunt bilirubin.
Bilirubin from erythropoietic heme is produced by monocytic macrophages, reticulo-endothelium, in every
organ but especially in the spleen, liver and bone marrow in order of importance.. The bilirubin from non-
erythropoietic hepatic heme is produced in the hepatocytes.
The tetrapyrrolic ring of heme is broken by an oxygenase at the alpha bridge, the bond between the
two carbons opposite to the gamma bridge which is between the two carbons carrying the two propionic
acids. The tetrapyrrolic molecule from a ring is transformed into a tetrapyrrolic chain without iron.
HEME + Heme oxygenase = OXY- HEME ( closed tetrapyrrolic ring with iron)
OXY- HEME + heme reductase = BILIVERDIN (open tetrapyrrolic ring without iron)
BILIVERDIN + biliverdin reductase = BILIRUBIN (unconjugated)
Pathology of bilirubin production
Hyprbilirubinimia with jaundice occurs in increased destruction of red blood cells namely:
hemolysis. It occurs in 1)congenital disorders of red cells (sickle cells, thalassemia, spherocytosis), 2)
immune hemolysis (erythroblastosis fetalis, 3) acquired diseases of red cells (dyserythropoiesis), etc.
In the adult, even a marked hemolysis does not produce significant increase of serum bilirubin if the
hepatic bilirubin clearance is normal. In the newborn, however, a marked hemolysis will be catastrophic.
At levels of 20mg/dl of serum bilirubin the infant will be deeply jaundiced and will develop kernicterus
(Nuclear jaundice: a grave form of yellow staining and degeneration of intracranial gray matter especially
of lenticular nucleus, ammon,s horn and subthalamic area).
Phototherapy is used for treatment of hyerbilirubinemia in neonates.
Bilirubin is a photoreceptor. The blue light transforms bilirubin into colorless products of oxidation which
are excreted in the urine.
Synthetic porphyrins containing tin or zinc instead of iron cause decrease of bilirubin formation by
competing for the heme oxygenase activity of macrophages. These compounds have been used in the
treatment of hyperbilirubinemia in animals and humans (e.g. Gilberts syndrome) with limited success.